Treatment of dermatomyositis secondary to refractory acute myelogenous leukemia with azacitidine :a case report and literature review
10.3760/cma.j.cn101721-20240723-00229
- VernacularTitle:阿扎胞苷治疗难治性急性髓系白血病继发皮肌炎1例并文献复习
- Author:
Jichun SHEN
1
;
Juan MU
Author Information
1. 武警部队特色医学中心内分泌与血液科，天津 300162
- Keywords:
Azacytidine;
Acute myelogenous leukemia;
Dermatomyositis
- From:
Clinical Medicine of China
2024;40(6):433-436
- CountryChina
- Language:Chinese
-
Abstract:
The patient was a 60-year-old female. Acute myelogenous leukemia (AML) was diagnosed. Azacytidine acts as a DNA transferase inhibitor can treat acute myelogenous leukemia. After treatment with azacitidine, the patient developed multiple red papules on the facial skin, which were pathologically confirmed as dermatomyositis. Dermatomyositis may be induced by azacitidine in the treatment of myelodysplastic syndrome (MDS) and acute myelogenous leukemia, but the dermatomyositis will disappear after hormonal and immunosuppressive therapy.
